PharmACT AG

PharmACT also developed medical device that is a respiratory protection mask to mitigate the spread of infectious diseases that are spread through the air. The device consists of a mask, filters, a harness, a blower, and a charger. It was intended to be used by medical professionals as they faced COVID-19 patients daily during the first few waves of the COVID-19 pandemic.

In 2020, PharmACT starteddeveloped developinga rapid COVID-19 teststest for home use so that users testing positive could detect if they had the virus from their own home and presumably quarantine so as toand not spread the virus. PharmACT partnered with several other healthcare and pharmaceutical companies during the early days of the COVID-19 pandemic to develop the rapid tests. Partnerships included Vivera Pharmaceuticals, and the two companies released a rapid test to diagnose COVID-19 in March 2020.

Pharmact Holding AG is a platform to the subsidiaries, each with different responsibility, production, approval of drug or distribution of various products.

Pharmact Holding AG is a platform to the subsidiaries, each with different responsibility, production, approval of drug or distribution of various products.

The company owns various patents and other intellectual property rights. These rights are made available to the subsidiaries, each of which has a core responsibility in the areas of research & development, production, distribution and organization.

Since May 2020, international distribution has been coordinated from Mannheim. In the United States, we are represented by Pharmact Healthcare Inc. in Tampa, Florida. Both sites are part of the plan to support the necessary studies for the approval of our patented active ingredient.

Pharmact is a biopharmaceutical company which has used its broad expertise in the treatment of arteriosclerosis to successfully complete the development of a new therapeutic drug for a number of diseases.

Since its foundation in 2014 in Berlin, the company was been financed exclusively by the shareholders and private investments.

The company has developed the new molecule by using a genetic engineered technology process. Meanwhile, patent applications for the substance and a number of different treatments have been filed worldwide. The novel substance provides us with the platform for the approval process we have initiated in Europe, the USA and possibly other sites in the same time.

The active ingredient has been produced in several batches for approval as a drug. By the end of Q4. 2020, the proof of concept has been demonstrated in an animal test series in the USA. The further steps are prepared or in progress, such as toxicology and drug safety. The clinical trial of the drug “BelACT” will be performed in parallel at different sites worldwide. We have initiated the necessary tasks for the regulatory process and prepared the complete study planning for Phase I / II / III.

The German Federal Institute for Drugs and Medical Devices (BfArM) discussed our study planning with us at the end of 2021. The BfArM has provided us with different questions which will be part of the approval planning for the active ingredient.

The project coordination is carried out in collaboration with various, highly specialized service providers and partners who accompany us on our path to medical approval.

Commercially and scientifically, all work packages are structured and costs are planned.

PharmACT is a Germany-based company that specializes in creating solutions that provide early detection of diseases. It was founded in 2014 and has several locations throughout Germany and the United States.

PharmACT offers several diagnostic and medical products to detect and prevent the spread of disease. The company focuses on developing, manufacturing, and distributing diagnostics for multiple types of diseases.

We will need additional capital until Phase I and II. This can be done through a convertible bond or a capital increase in 2022. We invite professional investors to support us on our way and become part of Pharmact.

If you are interested in investing in Pharmact? Then simply contact us via email. Write to “Investor”.

PharmACT also developed medical device that is a respiratory protection mask to mitigate the spread of infectious diseases that are spread through the air. The device consists of a mask, filters, a harness, a blower, and a charger. It was intended to be used by medical professionals as they faced COVID-19 patients daily during the first few waves of the COVID-19 pandemic.

In 2020, PharmACT started developing rapid COVID-19 tests so that users could detect if they had the virus from their own home and presumably quarantine so as to not spread the virus. PharmACT partnered with several other healthcare and pharmaceutical companies during the early days of the COVID-19 pandemic to develop the rapid tests. Partnerships included Vivera Pharmaceuticals and the two companies released a rapid test to diagnose COVID-19 in March 2020.

We will need additional capital until Phase I and II. This can be done through a convertible bond or a capital increase in 2022. We invite professional investors to support us on our way and become part of Pharmact.

If you are interested in investing in Pharmact? Then simply contact us via email. Write to “Investor”.

Commercially and scientifically, all work packages are structured and costs are planned.

The project coordination is carried out in collaboration with various, highly specialized service providers and partners who accompany us on our path to medical approval.

The German Federal Institute for Drugs and Medical Devices (BfArM) discussed our study planning with us at the end of 2021. The BfArM has provided us with different questions which will be part of the approval planning for the active ingredient.

The active ingredient has been produced in several batches for approval as a drug. By the end of Q4. 2020, the proof of concept has been demonstrated in an animal test series in the USA. The further steps are prepared or in progress, such as toxicology and drug safety. The clinical trial of the drug “BelACT” will be performed in parallel at different sites worldwide. We have initiated the necessary tasks for the regulatory process and prepared the complete study planning for Phase I / II / III.

The company has developed the new molecule by using a genetic engineered technology process. Meanwhile, patent applications for the substance and a number of different treatments have been filed worldwide. The novel substance provides us with the platform for the approval process we have initiated in Europe, the USA and possibly other sites in the same time.

Since its foundation in 2014 in Berlin, the company was been financed exclusively by the shareholders and private investments.